Ketamine Hydrochloride is named as an intervention in 9 current clinical trials in our Canada, Italy, Germany, Spain, Austria, Poland and Norway registers. 7 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Dr. Inge Winter (1). The most-studied condition is Major Depressive Disorder. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Ketamine Hydrochloride. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Ketamine maintenance treatment for depression: A multicenter open-label randomized controlled trial
2025-521330-29-00 · CTIS ↗ · Therapeutics
|
Phase 2 | Authorised | Ostfold Hospital Trust | Norway |
| Condition (as registered) | Trials |
|---|---|
| Major Depressive Disorder | 4 |
| Treatment Resistant Depression | 3 |
| Major Depressive Disorder (MDD) | 2 |
| Post Traumatic Stress Disorder | 1 |
| Obsessive-Compulsive Disorder | 1 |
| Somatoform Disorders | 1 |
| Depression | 1 |
| Alcohol Use Disorder | 1 |
| Suicide | 1 |
| Mechanical Ventilation | 1 |
| Critically Ill Intensive Care Unit Patients | 1 |
| Postoperative Pain | 1 |
| Opioid Use | 1 |
| Borderline Personality Disorder (BPD) | 1 |
| Treatment-Resistant Major Depressive Disorder | 1 |
| Treatment-resistant Bipolar Depression | 1 |
| Suicidal Ideation | 1 |
| Lead sponsor | Trials |
|---|---|
| Dr. Inge Winter | 1 |
| Università Vita-Salute San Raffaele | 1 |
| Medical University of Gdansk | 1 |
| University Hospital of North Norway | 1 |
| University Health Network, Toronto | 1 |
| McMaster University | 1 |
| Ciusss de L'Est de l'Île de Montréal | 1 |
| Joshua Rosenblat | 1 |
| The Royal's Institute of Mental Health Research | 1 |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
9 current trials in our Canada, Italy, Germany, Spain, Austria, Poland and Norway registers name Ketamine Hydrochloride (also registered as N01AX03) as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 7 of the 9 trials are recruiting: 4 with sites in Canada, 2 with sites in Italy, 1 with sites in Germany, 1 with sites in Spain, 1 with sites in Austria and 1 with sites in Norway. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Dr. Inge Winter (1), Università Vita-Salute San Raffaele (1), Medical University of Gdansk (1) and University Hospital of North Norway (1), among 9 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ketamine Hydrochloride works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ketamine Hydrochloride works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ketamine Hydrochloride (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.